BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 25311381)

  • 21. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of serum atherogenic risk in liver transplant recipients: Role of lipoproteins and metabolic and inflammatory markers.
    Chhatrala R; Siddiqui MB; Stravitz RT; Driscoll C; Sanyal A; Sargeant C; Luketic V; Sharma A; Sterling R; Matherly S; Puri P; Siddiqui MS
    Liver Transpl; 2015 May; 21(5):623-30. PubMed ID: 25762084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor.
    Konishi K; Miyake T; Furukawa S; Senba H; Kanzaki S; Nakaguchi H; Yukimoto A; Nakamura Y; Watanabe T; Koizumi Y; Yoshida O; Tokumoto Y; Hirooka M; Kumagi T; Abe M; Matsuura B; Hiasa Y
    Atherosclerosis; 2020 Apr; 299():32-37. PubMed ID: 32203743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.
    Santos RD; Valenti L; Romeo S
    Atherosclerosis; 2019 Mar; 282():110-120. PubMed ID: 30731283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 26. The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study.
    Tutunchi H; Naeini F; Ebrahimi-Mameghani M; Mobasseri M; Naghshi S; Ostadrahimi A
    Int J Clin Pract; 2021 Jun; 75(6):e14131. PubMed ID: 33683797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.
    Musso G; Cassader M; De Michieli F; Rosina F; Orlandi F; Gambino R
    Hepatology; 2012 Sep; 56(3):933-42. PubMed ID: 22684858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimated small dense low-density lipoprotein cholesterol and nonalcoholic fatty liver disease in nonobese populations.
    Huang H; Xie J; Hou L; Miao M; Xu L; Xu C
    J Diabetes Investig; 2024 Apr; 15(4):491-499. PubMed ID: 38108613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease.
    Ercin CN; Dogru T; Genc H; Celebi G; Aslan F; Gurel H; Kara M; Sertoglu E; Tapan S; Bagci S; Rizzo M; Sonmez A
    Metab Syndr Relat Disord; 2015 Sep; 13(7):319-25. PubMed ID: 26011302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis.
    Arulanandan A; Ang B; Bettencourt R; Hooker J; Behling C; Lin GY; Valasek MA; Ix JH; Schnabl B; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1513-20.e1. PubMed ID: 25661453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased atherogenic lipoprotein profile in children with non-alcoholic steatohepatitis.
    Castillo-Leon E; Connelly MA; Konomi JV; Caltharp S; Cleeton R; Vos MB
    Pediatr Obes; 2020 Sep; 15(9):e12648. PubMed ID: 32367624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes.
    Lomonaco R; Bril F; Portillo-Sanchez P; Ortiz-Lopez C; Orsak B; Biernacki D; Lo M; Suman A; Weber MH; Cusi K
    Diabetes Care; 2016 Apr; 39(4):632-8. PubMed ID: 26861926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.
    Pacifico L; Bonci E; Marandola L; Romaggioli S; Bascetta S; Chiesa C
    World J Gastroenterol; 2014 Dec; 20(45):17107-14. PubMed ID: 25493023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Meroni M; Longo M; Lombardi R; Paolini E; Macchi C; Corsini A; Sirtori CR; Fracanzani AL; Ruscica M; Dongiovanni P
    Hepatol Commun; 2022 Mar; 6(3):535-549. PubMed ID: 34677008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
    Siddiqui MS; Parmar D; Sheikh F; Sarin SK; Cisneros L; Gawrieh S; Momin T; Duseja A; Sanyal AJ
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2597-2605.e2. PubMed ID: 36731585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.
    Nadinskaia M; Maevskaya M; Ivashkin V; Kodzoeva K; Pirogova I; Chesnokov E; Nersesov A; Kaibullayeva J; Konysbekova A; Raissova A; Khamrabaeva F; Zueva E
    World J Gastroenterol; 2021 Mar; 27(10):959-975. PubMed ID: 33776366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD.
    Polyzos SA; Perakakis N; Boutari C; Kountouras J; Ghaly W; Anastasilakis AD; Karagiannis A; Mantzoros CS
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e390-400. PubMed ID: 31690932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?
    Gambino R; Cassader M; Pagano G; Durazzo M; Musso G
    Hepatology; 2007 May; 45(5):1097-107. PubMed ID: 17464986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of serum retinoic acid with hepatic steatosis and liver injury in nonalcoholic fatty liver disease.
    Liu Y; Chen H; Wang J; Zhou W; Sun R; Xia M
    Am J Clin Nutr; 2015 Jul; 102(1):130-7. PubMed ID: 25948673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.
    Imajo K; Hyogo H; Yoneda M; Honda Y; Kessoku T; Tomeno W; Ogawa Y; Taguri M; Mawatari H; Nozaki Y; Fujita K; Kirikoshi H; Saito S; Sumida Y; Ono M; Wada K; Nakajima A; Eguchi Y
    PLoS One; 2014; 9(12):e115403. PubMed ID: 25541989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.